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1. Introduction 
Basal cell carcinoma is the most frequently occurring skin tumor. Most cases are not life 
threatening. Only a very small proportion of BCCs metastasize. A high tendency to 
recurrence makes characterizing BCCs and tumor margin areas obligatory. It will assist in 
better understanding their pathogenesis and in more effective treatment through prevention 
of recurrence and second primary disease. In addition to histopathological assessment, the 
spread of the primary tumor according to TNM classification is crucial for estimating the 
further development of the disease. 
1.1 Molecular alterations involved in the emergence and development of basal cell 
carcinomas (BCC) 
While it has not been fully clarified which primary cell gives rise to basal cell carcinomas it 
is supposed that BCCs arise from interfollicular basal cells, keratinous cells of hair follicles 
or sebaceous glands (1 to 6). Chemically induced BCCs were produced in the pilosebaceous 
structures of rats (3, 7). Solar ultraviolet radiation (UVR), in particular ultraviolet B (UVB, 
waveband 280-315 nm), is a major and significant factor (8 to 23) in many of the carcinogenic 
steps leading to basal cell carcinomas. Additional risk factors are predisposing syndromes 
and genetic predisposition (3, 11 to 14, 16, 19, 24 to 41), such as skin-type (13, 42, 43), viral 
infections, above all human papilloma viruses (HPV) and / or immunosuppression (3, 13, 
17, 20, 35, 39, 41, 44 to 46). The influence of UVB is evident from the fact that BCC incidence 
is lowest in Finland (47, 48) and highest in Australia (13, 47 to 51). Incidence increases with 
advancing age through the accumulation of UV-radiation (52, 53). UVB exposure and 
chronic oxidative stress (54) effect direct DNA damage, mutations and chromosome 
aberrations in the skin (41, 55 to 57), all of which are found in basal cell carcinomas. They are 
comparable with squamous cell carcinomas (58) insofar as field cancerization can be shown 
in the environment of the BCC (59 to 63). The BCC can be characterized by certain markers 
such as proof of p53. Figure 1 illustrates UVB damage with regard to the mutation and 
inactivation of tumor suppressor gene p53 as well as activation of telomerase during 
cancerization, particularly in basal cell carcinomas (64).  
The inactivation of tumor suppressor activity is a universal step in the development of 
human cancers (65, 66). With  inactivation p53 looses its function as the “guardian of the 
genome” (66) thanks to which it normally controls, among other things, the normal cell 
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cycle, arresting irregularly growing cells via G1 / G2 transition of the cell cycle and 
compelling them to programmed suicide, apoptosis (67 to 76). bcl-2 can block and control 
p53-dependent apoptosis and loss of bcl-2 stimulates apoptosis (67 to 71, 73, 77, 78). While 
wild-type p53 suppresses cell growth, p53 mutations reduce DNA repair, for example after 
UVB radiation, and stop apoptosis. That can explain the increased incidence of skin tumors 
such as basal cell carcinoma through UVB radiation (13, 79 to 82).  
 
Fig. 1. Carcinogenesis of basal cell carcinomas. Concept for the course of molecular changes 
in the cancerogenesis of basal cell carcinomas: adapted and reprinted by permission of the 
American Association for Cancer Research: Ueda et al. (64) (Tel+ = telomerase activation). 
1.2 Molecular markers for differentiation of BCC and SCC of the skin 
Basal cell carcinomas and squamous cell carcinomas of the skin are differentiated by means 
of histopathological staining, mostly with hemalaun-eosin staining. This can lead to 
difficulty, as seen for instance in cytology. Vega-Memije et al. (83) introduced Papanicolaou 
staining to successfully distinguish between the two carcinoma types, and this was also 
used by Christensen et al. (84) along with May-Grünwald-Giemsa staining for the 
cytological differentiation of BCCs and actinic keratosis. Tellechea et al. (85) used 
immunohistochemical anti-Ber-EP4 monoclonal antibody. The total of 22 BCCs showed 
positive reactions, while in 21 SCCs the reaction was negative, proving this monoclonal 
antibody suitable for differentiating between the two nonmelanomatous skin-tumors. It was 
confirmed by Beer et al. (86) who verified expression of Ber-EP4 in all of 39 BCCs and in 
none of 23 SCCs tested. Swanson et al. (87) were able to distinguish BCCs both from SCCs of 
the skin and from trichoepitheliomas (TE) with proven expression of Ber-EP4 (also of bcl-2 
and CD34): The reaction of Ber-EP4 was positive in all of 44 BCCs, in 81% (29/36) of TEs and 
in none of 22 SCCs. According to the same procedure, Tope et al. (88) differentiated between 
BCC, actinic keratosis (AK) and SCCs: All of 5 superficial BCCs were Ber-EP4 positive, while 
all of 10 AKs and of 8 SCCs were negative. To differentiate between BCCs and SCCs the Ber-
EP4 marker is the most suited. Swanson et al. (87) differentiated with CD34 BCCs, SCCs and 
TEs: CD34 was positive in 16% (7/43) of BCCs, in 25% (5/20) of SCCs and in 8% (3/36) of 
TEs. Likewise, Yada et al. (89) and Aiad and Hanout (90) were able to discriminate BCC 
from SCC immunohistochemically with CD10. In the study by Yada et al. (89) BCCs 
expressed CD10 1+ to 2+ in 86% (44/51) and in all 9 SCCs CD10 was negative. According to 
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Aiad and Hanout (90) CD10 expression was significantly higher in BCCs than in SCCs: 
10/21 (48%) and 0/16 SCC (p=0.002). 
Guttinger et al. (91), Seelentag et al. (92), Dietrich et al. (93) and Seiter et al. (94) used 
immunohistochemical methods with monoclonal anti-CD44s and various anti-CD44 splice 
variant antibodies to differentiate BCCs and SCCs. Guttinger et al. (91) obtained distinct 
marking of tumor cells (++) in all SCCs with anti-CD44s, CD44v4, CD44v6 and CD44v9 
antibodies. The nodular BCCs showed no expression and the sklerodermiform BCCs (+) a 
weaker expression. This result was congruent with studies by Seelentag et al. (92). 
Seelentag et al. observed the expression of CD44s, CD44v3, CD44v4, CD44v6 and CD44v9 
in immunohistochemical paraffin sections. They (92) achieved higher or distinctly higher 
expression of CD44v3, CD44v5, CD44v6 and CD44v9 in SCCs of the skin (n=37) than in 
BCCs (n=10). In BCCs the expression was low (CD44s, CD44v3) or absent (CD44v4). 
Higher expression in BCCs was found with the splice variants CD44v5, CD44v6 and 
CD44v9. In squamous cell carcinomas Seelentag et al. (92) found CD44v3, CD44v5, 
CD44v6 and CD44v9 expression comparable with that in keratoacanthomas (n=12). CD44s 
and CD44v4 expression was lower in SCCs than in keratoacanthomas. This contradicted 
the findings by Dietrich et al., (93) who demonstrated CD44v4, CD44v5 and CD44v6 both 
in BCCs (n=7) and in SCCs (n=6). Indeed, using immunohistochemical methods Dietrich 
et al (93) demonstrated expression of CD44v7/8 and CD44v10 in all BCCs but in none of 
the SCCs tested. Forming groups according to the estimated percentage of staining cells, 
Seiter et al. (94) assessed expression of CD44s, CD44v5, CD44v6, CD44v7, CD44v7/8 and 
CD44v10 semiquantitatively. In the BCCs and SCCs they investigated, CD44s was 
expressed in the same degree, while all splice variants tested showed higher expression in 
SCCs. Simon et al. (95) checked the suitibility of immunohistochemistry for definite 
distinction between BCCs and SCCs with splice variants CD44v3, CD44v4, CD44v5, 
CD44v6, CD44v7/8 or  CD44v10. All splice variants stained the tumor center of BCCs, 
while in SCCs only tumor periphery was marked.  12/17 BCCs (71%) were positive with 
CD44v3 and 13/17 (77%) with CD44v5. The remaining CD44-splice variants marked all 
BCCs, and all of 16 SCCs were marked with all CD44-splice variants. In an 
immunohistochemical study by Son et al. (96), 49% of BCCs and only 35% of SCCs 
showed CD44v6 marking.  
Al-Sader et al. (97) sought to differentiate immunohistochemically the proliferative 
indices between BCCs and SCCs. The median scores of the mitotic index were 5 for BCCs 
and 4 for  SCCs (p=0.621), but the authors (97) observed that the median scores of Ki-67 
were significantly different, amounting to 271 (per 1000 cells) in BCCs and 340 (per 1000 
cells) in SCCs (p=0.029). To differentiate BCCs from skin-SCCs, Park et al. (98) used 
immunohistochemical proof of p53, p63 and survivin. With p53 the authors were unable 
to differentiate between the two, which were malignant in differing degrees: 90% 2+ to 3+ 
vs. 100% 2+ to 3+. Proof of p63 made this distinction possible: BCC 90% 2+ to 3+, SCC 
40% 2+, as did proof of survivin (BCC 40% 2+, SCC 80% 2+ to 3+). However, Bäckvall et 
al. (99) succeeded in demonstrating a significant difference between normal skin adjacent 
to BCC and that adjacent to SCC (p<0.05) with regard to the number of p53 clones. Chang 
et al. (100) found significantly less Ki-67 in 10 BCCs investigated (mean score value 12±7) 
than in 8 SCCs (mean score value 47±21), (p<0.05), and detected clearly different 
expression of p53 (mean score value BCC 50±17 vs. SCC 61±15). Son et al. (96) used 
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immunohistochemical findings of Ki-67 and p53 to differentiate BCCs (n=108) from SCCs 
(n=94). Ki-67 expression was low in 90% of BCCs and high in 10%, while Ki-67 showed 
high expression in 27% of SCCs and low expression in 73%. p53 was demonstrated in 15% 
of BCCs and in 46% of SCCs. Bolshakov et al. (101) succeeded in establishing clear 
differences between aggressive SCCs / nonaggressive SCCs and also aggressive BCCs / 
nonaggressive BCCs through mutation frequency of p53 with single-strand conformation 
polymorphism and sequencing: frequency of p53 mutations amounted to 35% (28/80) of 
aggressive SCCs vs. 50% (28/56) of nonaggressive SCCs as opposed to 66% (35/50) of 
aggressive BCCs vs. 38% (37/98) of nonaggressive BCCs. Chang et al. (100) also 
demonstrated a clear differentiation between BCC and SCC by immunohistochemical bcl-
2 detection: All of 10 BCCs displayed positive marking that was absent in all of 8 SCCs. In 
consonance with this, Delehedde et al. (80) found immunohistochemically distinct bcl-2 
expression (+++) in 17 BCCs examined, which was missing in all of 14 SCCs (p<0.05). 
Likewise, Swanson et al. (87) found positive bcl-2 reaction in 91% (41/45) of BCCs and in 
18% (4/22) of SCCs. Contrary to these results Al-Sader et al. (97) observed no difference 
between the median scores of the apoptotic index in BCCs (10.5 apoptotic cells / 1000 
cells) and in SCCs (10 apoptotic cells / 1000 cells). 
In our studies we introduced proof of telomerase activity to differentiate BCCs from SCCs 
(102 to 104), cf. 2.4.1: the proportion of BCCs with activation of telomerase amounted to 87% 
(26/30) and was barely higher than in SCCs of the skin with 75% (9/12). This result is in 
approximate conformity with synoptic references: activation of telomerase in 87% (177/203) 
of BCCs examined altogether and in 77% (58/75) of SCCs of the skin (103, 104). However, 
our studies demonstrated that the score values of immunohistochemical proof with APAAP 
(105) of the telomerase subunit hTERT cannot be used to differentiate between BCCs (n=24) 
and SCCs (n=7) of the skin (106, 107): BCC mean score value 9.4±4.9 (Ab 1: anti-hTERT 
antibody Calbiochem, USA, code 582005) and 9.0±4.0 (Ab 2: anti-hTERT antibody code 
NCL-hTERT Novocastra, UK, clone 44F12,) vs. SCC mean score value 9.9±2.4 (Ab 1) and  
9.1±3.8 (Ab 2), cf. 2.4.2. 
2. Molecular markers for basal cell carcinomas and tumor-free margin tissues 
Adequate resection of BCCs is of utmost importance in preventing recurrence (108 to 114). 
Other authors are therefore searching for markers which discriminate between basal cell 
carcinoma and histopathologically tumor-free margin. In addition to histopathological 
assessment, assessing the spread of the primary tumor (T1<2cm, T2 2cm) according to the 
TNM classification (115) is crucial for assessing further development of the disease. The risk 
of recurrence of each tumor is defined as closely as possible to enable choice and application 
of the most appropriate clinical procedure (51, 116, 117). Tumor size is important for 
prognosis of the disease, as is shown by comparison in Kaplan-Meier curves. With all due 
precaution given the many censored cases, we ascertain that patients with primary T2 
tumors relapse much earlier than those with T1 tumors (Log-rank p=0.003): after 14±2 
months (T2) vs. 65±16 months (T1), Figure 2. 
The classification in nonaggressive basal cell carcinomas and aggressive BCCs is 
predominantly determined by the clinical course of BCCs and by the tendency to recurrence: 
nonaggressive nodular, micronodular or superficial BCCs and aggressive infiltrative or 
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morphea BCCs (20, 81, 118 to 121). Additional markers will help to characterize and are 
essential for distinctly determining the spread of BCCs (19). 
 
Fig. 2. Up-to-date outcome in patients with BCCs and the spread of the tumor (T1 < 2cm, T2 
 2cm) in Kaplan-Meier curves. 
2.1 Different markers classifying nonaggressive and aggressive BCCs 
Staibano and colleagues classified between nonaggressive BCC1 without relapse and 
aggressive BCC2 with local recurrence during metaphylaxis. For this differentiation they 
introduced various markers. They detected high expression of p53 in 60% of 30 BCC2 
tumors and low expression in 10% of BCC1 tumors (122), or in 0/21 BCC1 tumors and in 
82% (18/22) of BCC2 tumors, respectively (123). Bolshakov et al. (101) were also able to 
discriminate clearly between aggressive BCCs and nonaggressive BCCs through 
determination of p53 mutations by single-strand conformation polymorphism and 
nucleotide sequencing: the frequency of p53 mutations was 66% (33/55) with aggressive 
BCCs and only 38% (37/98) with nonaggressive BCCs. In 11 aggressive BCCs Ansarin et al. 
(121) found significant immunohistochemical nuclear staining of p53 in more than 50% of 
tumor cells and in 33 nonaggressive BCCs in less than 50% of tumor cells (p<0.01).    
In BCC1 tumors the AgNOR scores were 6.56±1.98 and in BCC2-tumors 9.48±2.12: De 
Rosa et al. (119). When Staibano et al. (124) ascertained the apoptotic index, they found a 
marked difference: BCC1 5.98±2.52% vs. BCC2 39.82±8.32%. BCC1 tumors examined 
showed a distinct cytoplasmic staining of bcl-2. This marker was missing in all of the 30 
BCC2 tumors examined by Staibano et al. (122). In agreement with these investigations 
Ramdial et al. (81) detected a distinctly higher bcl-2 expression in  immunohistochemical 
assays in nonaggressive BCCs than in aggressive BCCs: 45/50 (90%) nonaggressive BCCs 
expressed bcl-2 2+ to 4+ and 22/25 (88%) aggressive BCCs maximally 2+. High expression 
of cyclin D1 was not found in any BCC1 tumors but in all of 30 BCC2 tumors (125). By 
determining DNA ploidy Staibano et al. (125) were also able to differentiate between 
BCC1 and BCC2: All BCC2 tumors were aneuploid as against 77% of BCC1 tumors. After 
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immunohistochemical staining for monoclonal antibody against factor VIII (von 
Willebrand factor), microscopic counts of microvessels revealed a statistically significant 
difference: mean score value BCC1 25.76±2.21 vs. BCC2 46.76±2.54 (126). 
Histopathological diagnostics using these markers can be supplementary evidence for the 
surgeon deciding on the surgical procedure for therapy. 
2.2 Examination of BCC spread by means of anti-CD44 antibodies and anti-splice 
variant antibodies, by anti-E48 and anti-U36 antibodies 
Cell adhesion molecules such as CD44 splice variants can be used as selective markers for 
different tumors and are important both for the diagnosis and prognosis of some tumors 
(127 to 129). Squamous cell carcinomas with poor differentiation display downregulation of 
CD44v6 expression in comparison with squamous cell carcinomas with high differentiation. 
Hyckel et al. (130) planimetered the immunohistochemical reaction of oral SCCs by anti-
CD44 monoclonal antibodies and confirmed an inverse relation to carcinoma grading. Our 
immunohistochemical findings in frozen sections with APAAP (105) in regard to squamous 
cell carcinomas of the head-and-neck region (131 to 133) are comparable with the 
downregulation of isoforms containing CD44v6 that  Salmi et al. (134) observed with 
CD44v3 and CD44v6 in SCCs in the head-and-neck area.  
Guttinger et al. (91), Baum et al. (135), Seelentag et al. (92), Seiter et al. (94), Simon et al. (95), 
Kooy et al. (136), Dingemans et al. (137, 138) and Son et al. (96) used immunohistochemical 
marking on BCCs with CD44v6 and found it better than hemalaun-eosin staining for 
identifying their local spread. In 20 BCCs, Seelentag et al. (92) found  low or no expression of 
CD44s or CD44v4, contrary to SCCs with low expression of CD44v3. The authors found 
high expression of CD44v5, CD44v6 and CD44v9 in BCCs, but the expression was lower 
than in SCCs. 
We had previously achieved better results discriminating squamous cell carcinomas of the 
head and neck from their surroundings with immunohistochemical APAAP (105) in small 
frozen sections by using adhesion molecules CD44v6 (also its chimera U36) and E48 (131 
to 133). This method was now confirmed in BCCs.  We accomplished APAAP (105, cf. 131, 
132) with a monoclonal antibody against the adhesion molecule CD44v6 (clone VRR-18, 
Bender, Austria) and with two monoclonal antibodies against adhesion molecules E48 
(Centocor B.V., Netherlands) and U36 (Centocor B.V., Netherlands). Antibody E48 has 
been developed to recognize normal squamous epithelium and squamous cell carcinomas 
(139). It is well suited for differentiating carcinomas from negative adenocarcinomas and 
small cell carcinomas (140). Monoclonal anti-U36 antibody is an anti-CD44v6-chimeric 
(mouse/human) antibody for marking normal human squamous epithelia and squamous 
cell carcinomas (141 to 143). The quantitative presentation of antigen expression (CD44v6, 
E48, U36) in frozen sections was evaluated in our study by means of an immunoreactive 
score (IRS) according to Remmele et al. (144) and Remmele and Stegner (145). Our 
evaluation was performed three times by an independent examiner. The membrane 
staining intensities (SI) were divided into 5 levels: negative, 1+ (weak expression) to 5+ 
(very strong expression). The percentage of positive stained cells (PP) was classified into 4 
groups according to percentage of stained cells: 0-<10%=score 1; 10-<50%=score 2; 50-
<75%=score 3; 75-100%=score 4. The IRS was calculated by multiplication of SI and PP. To 
identifying the spread of BCCs in small frozen sections we applied immunohistochemical 
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staining with APAAP (105) to membrane marking of CD44v6, E48 and U36. We found it 
better than hemalaun-eosin staining.  
In our study the immunoreactive scores (IRS) in BCC tumor center vs. tumor-free margin 
were demonstrated and are illustrated in Figure 3. Only the expression of CD44v6 was 
significantly higher in tumor center (mean score value 12.5±3.2) than in squamous 
epithelia in the tumor margin (mean score value 8.4±4.0, p=0.006), and was comparable to 
the expression of Ki-67 (p<0.001). Microscopic representation with the three monoclonal 
antibodies, particularly CD44v6, distinguished BCCs clearly from their surroundings: 
Figure 4. 
The ample expression of  CD44v6 and U36 (if necessary E48) adhesion molecules might 
make them useful both for the diagnostics and adjuvant therapy of BCCs. Radionuclide-
labeled purified monoclonal antibodies were successfully developed in VU University 
Medical Center (Amsterdam/Netherlands). They have proven themselves in this capacity 
for years in the diagnostics (146 to 152) and therapy (142, 147, 153 to 156) of squamous cell 
carcinomas in the head-neck-region. 
 
 
 
 
 
 
Fig. 3. Immunoreactive scores (IRS, cf. 144, 145) of expression of CD44v6, E48 and U36 in 
basal cell carcinomas (mean values). 
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a) CD44v6 
 
b) E48 
 
c) U36 
 
 
Fig. 4. Comparison of expression of CD44v6 (a), E48 (b) and U36 (c) in small frozen sections 
of BCCs, magnification 200x. 
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2.3 Markers p53 and Ki-67 in BCCs and BCC-free tumor margin tissue 
Molecular alterations can be found during carcinogenesis and tumor growth. As illustrated 
schematically in Figure 1 (cf. 1.1), the inactivation of tumor suppressor gene p53 is an 
important step towards carcinogenesis. During inactivation and mutation of p53 mutated 
p53 protein is formed. Mutated and wildtype p53 protein can be detected 
immunohistochemically by different or identical antibodies, for instance in tissues with field 
cancerization after intensive solar irradiation (60, 62) as well as in tumor-free margin 
surrounding of BCCs (98, 157 to 161). Authors are therefore searching for markers such as 
p53 which discriminate between basal cell carcinoma and histologically tumor-free margin 
surrounding the tumor.   
2.3.1 Marker p53 in BCCs and BCC-free tumor margin tissues 
Urano et al. (157) applied immunohistochemistry using anti-p53 antibody clone Do-7, which 
recognizes both wildtype p53 protein and mutated p53 protein. The authors found 
significantly lower p53 expression in tumor margin than in tumor center (p<0.05): 7/17 
tissues of tumor margin (41%) and 11/17 (65%) of tumor center were p53 positive. Barrett et 
al. (158) were able to detect p53 in 20/27 (74%)  BCCs. They also investigated adjacent 
actinic keratosis in the tumor margin of 4 tumors and found increased p53 staining. 
Demirkan et al. (159) detected significantly less p53 in BCC-free  tumor margin than in the 
tumor center: 26% (11/42) p53 positive tumor-free margins vs. 44% (8/18) tumor center 
tissues (p=0.034), the same was found with monoclonal antibody Do-7 (DAKO/Denmark). 
According to investigations by Rajabi et al. (160), p53 expression in 96/123 BCC tumor 
tissues (82%) was not significantly higher than in 84/117 tumor-free margin tissues (78%), 
p=0.38. The relatively high p53 expression of the tumor margin could be related to strong 
sun exposure of uncovered skin with patients in southern latitudes. Bäckvall et al. (99) and 
Koseoglu et al. (161) were also unable to find a significantly decreased expression of p53 in 
adjacent tissues surrounding the BCCs. Koseoglu et al. (161) detected p53 clones in 10/43 
tumor center tissues (23%) and in 9/21 tumor margin tissues (42%).  
In our study we employed an antibody from Oncogene (USA) to ascertain p53 scores in 
small frozen sections: a monoclonal antibody against mutated p53 Ab-3 (OP 29-1) (103, 106, 
107). Before performing the APAAP (105), slides with frozen sections were fixed in 
methanol and acetone and pretreated in a steamer (95 to 99°C). This was non-essential  for 
p53 and Ki-67 but for hTERT and retinoic acid receptors nuclear staining in frozen sections 
essential (106, 107, 162). We determined p53 scores as described in 2.2. In quantitative 
presentation of antigen expression (p53, Ki-67, hTERT and retinoid receptors) by means of 
an immunoreactive score (IRS) we refer exclusively to the nuclear and / or nucleolar 
staining. We evaluated staining intensity (SI) and number of positive stained cells (PP) in the 
BCCs and in squamous cell epithelia of the tumor margin. The IRS was calculated by 
multiplication of SI and PP. In our immunohistochemical investigations the difference 
between IRS of p53 in tumor center (mean score value 7.9±3.4) was not significantly higher 
than in tumor margin (mean score value 5.8±4.2), p=0.095:  Figure 5 and illustrated in Figure 
6a (tumor center) and Figure 6c (tumor margin), cf. 2.3.2. p53 scores in T2-BCCs (8 primary 
tumors 2cm) were not higher than in T1-BCCs (17 primary tumors <2cm): mean score 
value 6.3±4.3 (T2) vs. 7.9±3.3 (T1), p=0.328. We tested the role of p53 scores investigated for 
prognosis in Kaplan-Meier curves (cf. 2.3.2). We divided all p53 scores (also Ki-67 scores and 
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hTERT scores) into two groups (group 1: scores < mean value, group 2: scores  mean value) 
and used the patients’ up-to-date outcome as documented in our hospital. With all due 
reservation due to the many censored cases, we ascertain that BCCs of patients with higher 
p53 scores in tumor center tissues recurred later, almost significantly later, than BCCs of 
patients with lower scores in tumor center tissues (65±16 months vs. 23±6 months): Log-rank 
p=0.059, Figure 7a. However, patients with higher p53 scores in BCC tumor margin tissues 
did not relapse significantly but nevertheless earlier than patients with lower p53 scores in 
tumor margin tissues (36±6 months vs. 40±11 months): Log-rank p=0.622, Figure 7c. 
 
Fig. 5. IRS (immunoreactive scores, cf. 144,  145) mean values of expression of mutated p53 
and of Ki-67 in basal cell  carcinomas. 
2.3.2 Marker Ki-67 in BCCs and BCC-free tumor margin tissues in comparison with 
p53  
Some authors compared proof of p53 with expression of the proliferation marker Ki-67. 
Healy et al. (163) proved 71 BCC tissues immunohistochemically with p53 and Ki-67, 17 
BCCs group 1 (patients without recurrence), 17 BCCs group 2-0 (patients who relapsed 
some time later) and 17 BCC relapses (group 2-R). p53 was demonstrated in 95% of each 
group. However, the authors (163) revealed significantly lower values of Ki-67 expression in 
BCCs in group 1 (mean value 12%) than in group 2-0 (mean value 25%) or group 2-R (mean 
value 22.5%): p=0.009. Barrett et al. (158) examined expression of p53, Ki-67 and PCNA in 27 
basal cell carcinomas and compared them to histopathological BCC types. Expression of p53 
and PCNA was higher in aggressive BCCs than in nonaggressive BCCs, and PCNA was 
higher than Ki-67.  Chang et al. (100) tested 10 BCCs and detected both p53 and Ki-67 in all 
of them. The labeling index with Ki-67 was significantly lower than with p53: 12±7 vs. 50±17 
(p <0.05). By contrast, in 20 BCCs Abdelsayed et al. (164) demonstrated higher marking with 
Ki-67 (mean value 51.25±6.06) and PCNA (mean value 52.25±7.57) than with p53 (mean 
value 31.75±9.02). Koseoglu et al. (161) also investigated the p53 level of 50 BCCs 
immunohistochemically in comparison with Ki-67 expression (anti-Ki-67 antibody clone Ki-
88). They found significantly higher Ki-67 expression in p53 positive tissues (Ki-67 mean 
value 14.66) than in p53 negative tissues (Ki-67 mean value 8.37): p=0.019. 
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Fig. 6. Comparison of expression of p53 (a, c) and Ki-67 (b, d) in small frozen sections of 
BCCs (a, b) and in tumor  margin tissues (c, d), magnification 400x. 
We also compared Ki-67 scores with p53 scores in tumor center tissues and tumor-free 
margin tissues. To prove Ki-67 in small frozen sections we used a monoclonal mouse anti-
human Ki-67 antibody (clone MIB-1) from DAKO (Denmark) (106, 107). As described under 
2.2 and 2.3.1, nuclear staining scores were achieved with immunohistochemical APAAP 
(105). The Ki-67 mean score value in tumor center (10.9±2.5) was significantly higher than 
that in tumor margin (7.4±1.8), p<0.05: Figure 5, cf. 2.3.1. Our results with p53 and Ki-67 
expression of tumor center and tumor margin tissues are displayed in Figure 6.  
We tested the prognostic prediction of Ki-67 status (107) detected in our patients’ tissues 
with BCCs in Kaplan-Meier curves. With all due reservation in view of the number of 
censored cases, patients with higher Ki-67 scores in tumor center tissues suffered BCC 
recurrence (not significantly) later (Log-rank p=0.560) than patients with lower Ki-67 scores 
(56±16 months, higher scores, vs. 27±7 months, lower scores): Figure 7b. In contrast, patients 
with higher Ki-67-scores in tumor margin tissues did not relapse significantly earlier (Log-
rank p=0.321) than patients with lower Ki-67-scores (35±5 months, higher scores, vs. 48±13 
months, lower scores): Figure 7d. 
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Fig. 7. Kaplan-Meier curves for p53 expression (a, c) and Ki-67 expression (b, d) in BCC 
tumor center tissues (a, b) and in tumor margin tissues (c, d). 
2.4 The biology of telomerase 
In 1984 Blackburn and Greider discovered telomerase in a single-celled ciliate Tetrahymena 
(165, 166), a ribonucleoprotein enzyme. The enzyme is of universal importance for cell 
proliferation. Telomerase replaces the mitotic loss of telomeres at chromosome ends with 
telomeric substitutes. This abrogates the limited cell division potential (the Hayflick limit). 
Hayflick and Moorhead (167) observed limited cell division in fibroblast cultures. Activation 
of telomerase occurs during embryogenesis (168, 169). In normal somatic tissues with a 
limited replicative potential telomerase activity can be demonstrated only in traces or not at 
all (170 to 172). Activation of telomerase can be found inside cells with proliferative 
potential such as stem cells, in strongly regenerative cells, and in dermal cells of hair follicles 
(169, 171 to 175). Telomerase can be activated by UVB in seriously sun-exposed skin (10, 64). 
It may also be detected in benign proliferative lesions (174) or after activation in cells of 
inflammatory reactions (170, 172, 174, 176 to 178). Reactivation of telomerase also occurs in 
carcinogenesis (179, 180), as was illustrated by Ueda et al. (64) (Figure 1, 1.1). It is an 
essential step for cancer immortalization and cancer progression (172, 180).  
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However not until Kim et al. (168) developed the polymerase chain reaction based telomeric 
repeat amplification protocol in 1994 (TRAP assay) was it possible to detect telomerase in 
greater numbers in unfixed tissues. Since then, a great number of tissues, particularly from 
cancer, have been investigated for telomerase activity as the reviews by Shay and Bacchetti 
(181) and Dhaene et al. (182) demonstrate.  
2.4.1 Activation of  telomerase in tumor center and tumor margin tissues of BCCs 
The results of telomerase activity in BCCs and tumor-free adjacent tissues have been 
summarized. The portion of 203 specimens with evidence of telomerase detected with the 
TRAP assay (168) amounted to an average of 87%, varying between 20 and 100% (64, 103, 
104, 183 to 189). Table 1 sums up telomerase activity of BCCs and tumor-free adjacent 
tissues. To discriminate between BCC center tissue and tumor-free margin tissue Taylor et 
al. (183) and Ueda et al. (64) introduced proof of telomerase activity. They found clearly less 
telomerase activity in tumor margin tissue than in the tumor center: BCC margin tissues 
with 67% and 39% vs. 95% and 85% of BCC center tissues. 
 
 
Table 1. The frequency of telomerase activity (detected with the TRAP assay) in basal cell 
carcinomas and their tumor-free margin tissues. 
Like Taylor et al. (183) and Ueda et al. (64), we found significantly higher telomerase activity 
in 26/30 (87%) of BCC tumor center tissues (mean value 661±388 mOD) than in 9/25 (36%) 
histopathologically tumor-free tumor margin tissues (mean value 187±233 mOD) (103, 104). 
As we proved telomerase activity semiquantitatively with a PCR-ELISA (Telo TAGGG 
Telomerase PCR and PCR-ELISA plus, Roche Diagnostics, Germany) we were able to be 
somewhat more precise:  the mean value of telomerase activation in BCC tumor tissues was 
significantly higher than in tumor margin tissues: p<0.001. In contrast, telomerase activation 
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in T2 tumors (mean value 564±225 mOD) did not differ significantly from telomerase 
activation in T1 tumors (mean value 709±446 mOD): p=0.783. In Figure 8, our study on 
telomerase activation in tumor center and tumor margin has been compiled according to 
extinction values. 
We tested whether the telomerase examined in BCCs or tumor margin tissues has 
prognostic relevance (103, 104). We divided all measured values of telomerase (PCR-ELISA) 
and divided the patients into two groups, group 1: < mean value and group 2:  mean value, 
and used the patients’ up-to-date outcome as documented in our hospital. In Kaplan-Meier 
curves of tumors and tumor margin tissues, patients with higher telomerase activity 
suffered recurrence earlier than patients with lower telomerase activity but not significantly: 
tumor center: 36±9 vs. 97±0 months (Log-rank: p=0.100), tumor margin: 19±1 vs. 42±6 
months (Log-rank: p=0.141): Figure 9. 
 
    
 
Fig. 9. Comparison of Kaplan-Meier curve for telomerase activity in BCCs (a) and tumor-free 
margin tissues (b). 
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Detection of telomerase activity in unfixed BCC tissues and tumor margin tissues can 
corroborate, with due reservation in view of the censored cases, histopathological and 
clinical assessment of risk of recurrence. 
2.4.2 Expression of hTERT in tumor center and tumor margin tissues of BCCs  
hTERT (human telomerase reverse transcriptase) is a catalytic subunit and a component of 
telomerase (171, 190, 191). Proof of hTERT protein can be carried out both in unfixed and in 
fixed tissue and facilitates the localization of telomerase activity. The detectable evidence of 
the hTERT protein or hTERT mRNA might, however, not always mirror detectable 
telomerase activity (171).  
Saleh et al. (189) used proof of hTERT to differentiate between BCCs of differing size and 
histopathological type. They determined hTERT in all of 12 BCCs, with no significant 
difference between mRNA hTERT by RTq-PCR in BCCs of different size: mean value BCCs 
<9 mm 0.458 vs. mean value BCCs 9 mm 0.478. In tumor-free margin tissues of larger BCCs 
the authors (189) found a somewhat lower, non-significant expression of hTERT mRNA 
(BCC <9 mm mean value 0.160, BCC 9 mm 0.119).  hTERT expression of superficial BCCs 
(n=5), however, was significantly lower (p<0.05) than that of nodular BCCs (n=7): tumor 
center mean value 0.305 vs. 0.525 and tumor-free margin 0.094 vs. 0.172. With senior patients 
(65 years of age, n=6) Saleh et al. (189) succeeded in determining non-significant hTERT 
expression in tumors and tumor-free margin tissues that was lower than that in younger 
patients (<65 years of age, n=6): tumor center mean value 0.343 vs. 0.593 and tumor margin 
0.104 vs. 0.175. Proof of hTERT was also established by Hu et al. (192) and Park et al. (98) for 
evaluating BCCs. Hu et al. (192) examined 62 fresh skin tissues in RT-PCR.  They compared 
hTERT with TPI (another protein component of telomerase) and with hTR, an RNA 
component of telomerase (171). Part of their study (192) was the investigation of 4 BCCs, all 
of which expressed hTERT, TPI and 3 / 4 hTR. Park et al. (98) demonstrated hTERT 2+ to 3+ 
in 8 / 10 BCCs in paraffin sections with anti-hTERT antibody from Calbiochem (USA, Ab-2). 
Ogoshi et al. (193) used in situ hybridization to prove hTERT and confirmed its occurrence 
in 93% (14/15) of BCCs.  
Attia et al. (194) introduced the anti-hTERT antibody code NCL-hTERT (clone 44F12, 
Novocastra, UK) for evidence of immunohistochemical hTERT in normal tissues such as in 
photo-exposed skin. The authors succeeded in proving hTERT (1+ to 3+) in 80% of the 
epidermis of photo-aged subjects. hTERT was expressed in normal skin in the basal layer 
and in some supra-basal layers, as well as in hair follicles (cf. telomerase activity in hair 
follicles: 173 to 175). 
In our study with small frozen sections we used eleven anti-hTERT antibodies to detect 
and localize hTERT expression in 25 BCC tumor tissues and 25 tumor margin tissues 
(107). Previously we had employed the same antibodies to examine squamous cell 
carcinomas and SCC tumor margin tissues (106). Before performing APAAP (105), slides 
were fixed in methanol and acetone and pretreated in a steamer (95 to 99°C). As described 
in detail in our first study (106), this pretreatment was essential for hTERT nuclear 
staining in frozen sections. The most prominent immunohistochemical effects were 
achieved with anti-hTERT antibody code NCL-hTERT (clone 44F12, Novocastra, UK), 
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which was also used by Attia et al. (194) for hTERT detection in sun exposed skin. This 
antibody was classified later in the paper by Wu et al. (195) as an antibody against 
nucleolin. We expanded our investigation and incorporated an anti-nucleolin antibody to 
clarify this issue (106, 107). On the basis of our peptide absorption studies (106) and in 
agreement with many authors we think that this antibody clone 44F12 Novocastra 
identifies hTERT. We compared the results of BCCs (107) with antibody Calbiochem, 
USA, code 582005 and others, and determined the hTERT scores as described in 2.2 and 
2.3.1. In the quantitative presentation of antigen expression we refer exclusively to the 
nuclear and / or nucleolar staining. We evaluated staining intensity (SI) and the number 
of positive stained cells (PP) in the BCCs and in squamous cell epithelia of the tumor 
margin. The IRS was calculated by multiplication of SI and PP (144, 145).  
Our immunohistochemical proof of hTERT is predominantly localized in tumor and in 
squamous cell epithelia of BCCs and BCC tumor-free margin tissues. hTERT scores with a 
polyclonal antibody (Calbiochem/USA, code 582005, Ab 1) and with a monoclonal antibody 
(Novocastra/UK, code NCL-hTERT, clone 44F12, Ab 2) are significantly lower in the tumor 
margin (mean score values Ab 1  5.4±3.3 and Ab 2  7.0±2.9) than in tumor center (mean score 
values Ab 1  9.4±4.9 and Ab 2 9.0±3.9): p=0.002 and p=0.011 (107). In Figures 10 and 11, 
hTERT expression is demonstrated with two antibodies. Proof of hTERT expression now 
and then differs from telomerase activity. 
 
 
 
 
 
 
Fig. 10. Mean values of immunoreactive score (cf. 144, 145) with two anti-hTERT antibodies 
(Calbiochem/USA and Novocastra/UK). 
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Fig. 11. Comparison of hTERT expression with two anti-hTERT antibodies: polyclonal 
antibody code 582005, Ab 1 ( a, c and e)  and monoclonal antibody code NCL-hTERT, clone 
44F12, Ab 2 (b, d and f), magnification 400x. 
Kaplan-Meier curves indicate that proof of hTERT does not reveal the further course of the 
disease. We divided all hTERT scores into two groups (group 1: < mean value, group 2:  
mean value) and related them with the patients’ up-to-date outcome as documented in our 
hospital.  With the caveat that there were many censored cases, it can be said that patients 
with higher hTERT scores in tumor center tissues relapsed earlier than patients with lower 
hTERT scores in tumor center tissues: antibody code 582005 (Ab 1): 43±8 months vs. 70±31 
months, Log-rank p=0.539, Figure 12a; antibody code NCL-hTERT (Ab 2): 42±9 months vs. 
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77±25 months, Log-rank p=0.387, Figure 12b. However, patients with higher hTERT scores 
in BCC tumor-free margin tissues did not relapse earlier than those with lower hTERT 
scores in tumor-free margin tissues: antibody code 582005 (Ab 1): 43±9 months vs. 30±9 
months, Log-rank p=0.230, Figure 12c; antibody code NCL-hTERT (Ab 2): 39±5 months vs. 
32±5 months, Log-rank p=0.686, Figure 12d. 
 
Fig. 12. Kaplan-Meier curves of hTERT expression in BCCs (a and b) and tumor-free margin 
tissues (c and d): Ab 1 = polyclonal antibody code 582005, Ab 2 = monoclonal antibody code 
NCL-hTERT. 
Our hTERT results in tissues from patients with basal cell carcinoma (107) verify the value 
of hTERT in localizing the cells in which telomerase is activated (2.4.1). Although we 
identified differences between eleven antibodies (106, 107), we succeeded in detecting 
hTERT expression primarily in tumor cells and in squamous epithelia cells (Figure 11) after 
pretreatment of frozen sections in the steamer. We applied the same unfixed tissues for 
proof of telomerase activity and for hTERT expression. As McKenzie et al. (171) had already 
discovered, our detection of hTERT might not always mirror detectable telomerase activity 
(Figure 11, a to f). Kyo et al. (196) arrived at the same conclusion that hTERT did not always 
correlate with telomerase activity of the various cell types. 
Given our previous observations, we decided to evaluate only nuclear or nucleolar 
expression of hTERT although some antibodies also displayed cytoplasmic staining (106, 
107). It must be mentioned, however, that investigations of gynaecologic carcinomatous 
tissues by Kyo et al. (196) established proof of both hTERT and high levels of telomerase 
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after the isolation of cytoplasms, so further evaluation for immunohistochemical proof of 
hTERT is warranted. Taken together, both telomerase and hTERT may be useful as 
biomarkers in predicting chemotherapeutic effects (197).  
3. Biomarkers for chemoprevention of basal cell carcinomas 
Given frequent BCC recurrence and field cancerization in tumor-free margin tissues, several 
studies were launched to investigate the efficacy of chemoprevention in patients with a 
basal cell carcinoma. The best and primary prevention of basal cell carcinomas is reduction 
of the most important risk factor, exposure to strong sunlight from childhood (11, 12, 15, 18, 
21, 23, 39, 52, 198).  The use of agents that inhibit the noxious influence of UV light (199) 
could therefore be the most effective preventive method. In addition, there have been many 
studies applying retinoids (topical and oral / systemic) to suppress the emergence of basal 
cell carcinomas (200 to 207) and thus influence field cancerization of skin and tumor 
surroundings (59 to 63) to prevent new tumors and / or tumor recurrences. For 
immunosuppressed patients, chemoprevention is particularly important (63, 198, 208 to 
210). After chemoprevention proved to be unsuccessful in most studies, receptor-selective 
retinoids such as tazarotene were tried out (211 to 218). Tazarotene is selective for retinoic 
acid receptors RAR and RAR. Thus Bianchi et al. (217) successfully applied tazarotene-gel 
preoperatively for small superficial and nodular BCCs. This was not successful on keratotic 
BCCs with high p53 expression, and they were operated afterwards. Crucial for effective 
retinoic acid chemoprevention and / or therapy is the expression of RAR- and RXR-
receptors (218, 219), as was demonstrated by So et al. (220). So et al. consider tazarotene to 
be the most appropriate agent to date for chemoprevention of BCCs.  
In addition to synthesis of suitable agents it is essential to search for suitable biomarkers to 
improve prevention (19), and markers such as p53, Ki-67 or telomerase (2.3 and 2.4) merit 
consideration along with other genetic markers. Intermediate markers are needed in particular 
for chemoprevention trials (204). To determine a preliminary endpoint, genetic, cellular, 
biochemical and immunological surrogate biomarkers  - surrogate endpoint markers (SEBs)  -  
are being used and validated so that BCC chemoprevention can be evaluated before a 
recurrence becomes evident (204, 221 to 225). Orlandi et al. (225) employed the markers Ki-67, 
p53, apoptosis-index, RAR, RAR and RAR before and after tazarotene therapy of 30 BCCs. 
Expression of Ki-67 was significantly reduced after therapy compared with controls (11% vs. 
29%, p<0.001). Expression of p53 was unchanged after therapy. In comparison with controls, 
however, evidence of apoptotic cells was significantly higher after therapy (4.5% vs. 1%, 
p<0.001). While expression of RAR and RAR was not changed through therapy, expression 
of receptor RAR was distinctly higher. In our model investigations with cell cultures of oral 
squamous cell carcinomas, telomerase proved to be a suitable biomarker before and after 
retinoid therapy (162). Verification with BCCs is yet to follow.  
Examination of RAR receptors (retinoic acid receptors) and RXR receptors (retinoid X 
receptors) on BCCs might indicate why most studies do not show any differences between 
therapy and placebo groups. Using immunohistochemical methods, Kamradt and Reichrath 
(226) investigated expression of RAR receptors in frozen sections of 15 basal cell carcinomas: 
RAR was most evident (3 +), RAR a little weaker (2 +) and RAR scanty (0 to 1 +). This 
corroborates studies by Hartmann et al. (227). In comparison with SCCs of the skin, the 
authors determined RAR receptors of 28 BCCs by RTq-PCR. Measured values of this study 
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were also lowest for RAR-mRNA (7.91 x 10 –5) and distinctly higher for RAR (1.97 x 10 –3) 
and RAR (1.25 x 10 –2). 
Approximately comparable with regard to tumor-free margin tissues are 
immunohistochemical investigations by Reichrath et al. (228) on normal skin RAR- and RXR 
receptors of 12 male volunteers. Expression of RAR was most distinctly detectable, among 
other things, in epidermal keratinocytes (5 +) and in hair follicle keratinocytes (5 +). 
Expression of RAR was distinct in epidermal keratinocytes (2 +) and in hair follicles (3 +), 
but expression of RAR was found in traces only (0 to 1 +). All three RXR receptors RXR, 
RXR and RXR were distinctly expressed (2 +, mostly 3 +) in both of these cell types.  
We therefore tested as well for expression of RAR and RXR receptors in small frozen sections 
of BCCs with immunohistochemical APAAP (105). After fixing pretreatment in a steamer, 
which was essential in our study for clear and strong nuclear receptor detection in frozen 
sections (162, cf. 106, 107), we applied antibodies from Santa Cruz / USA (anti-RAR, code sc-
551; anti-RXR1, code sc-556 and anti-RXR, code sc-555), from Abcam / USA (anti-RAR, 
code ab15515) and from Abnova / USA (anti-RXR, code H00006256 M01). Other antibodies 
were less suitable for our frozen sections. In our study the anti-RAR antibody was 
inappropriate (162). Evaluation succeeded with immunoreactive scores (IRS) as described with 
p53, Ki-67 and hTERT (2.3.1, 2.3.2 and 2.4.2). For control we investigated tissues with 
comparable localization from BCC-free patients. Figure 13 summarizes mean score values for  
 
 
Fig. 13. Immunoreactive scores (IRS, cf. 144, 145) of expression for RAR  and RXR receptors 
in small frozen sections of BCCs and control tissues (mean values). 
expression of RAR and RXR receptors. In agreement with Kamradt and Reichrath (226) and 
with Hartmann (227) we were able to detect all receptors tested in BCCs in similar levels as in 
control tissues. RAR expression in BCCs had the lowest value (mean score value 4.92±1.81), 
followed by RXR (mean score value 5.83±1.76), RXR (mean score value 7.83±2.36), RARα 
(mean score value 10.17±2.02) and RXR (mean score value 10.38±2.14). Expression of RAR 
was almost significantly lower in BCCs than in control tissues (p=0.056). The expression of the 
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remaining receptors in BCCs and control tissues did not differ statistically: p=0.586 (RAR), 
p=0.862 (RXR), p=0.863 (RXR) and p= 0.871 (RXR). 
Our results suggest that the increase of RAR  in the context of a chemoprevention might 
give us valuable information as a surrogate end point biomarker for the success of therapy 
in chemoprevention, as was previously demonstrated by Orlandi et al. (225).  Figures 14a to 
14e illustrate expression patterns of receptors in small frozen sections of basal cell 
carcinomas. 
 
 
 
Fig. 14. Expression of retinoic acid  receptors (RAR) and retinoid X receptors  (RXR) of a 
nodular BCC (frozen sections); bars 20 µm. 
e) RXR 
c) RXR                                                                  d) RXR 
a) RAR                                                                 b)RAR 
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4. Conclusion 
Immunohistochemical application of Ber-Ep4  (85 to 88) is particularly appropriate for 
histopathological differentiation between SCCs of the skin and basal cell carcinomas. When 
examined with immunohistochemical methods, adhesion molecules CD44v6 and U36 
(CD44v6-chimera) give clear evidence for spreading of BCCs (Figure 4) and for the absence 
of tumor in tumor margins (91 to 96, 134 to 138, cf. 131 to 133). Radionuclide-labeled 
antibodies developed against oral squamous cell carcinomas (146 to 156, 229, 230) might also 
be applied in the diagnosis and therapy of patients with BCC.  
It is important for prognostic purposes to make a clear distinction between smaller T1-BCCs 
and larger T2-BCCs (cf. 2. and Figure 2). Clinical classification into aggressive and less 
aggressive BCCs confirmed by histopathology can be supported, among other things, by 
markers p53 (101, 103, 121 to 124, 157 to 161), bcl-2 (81, 100, 122), Ki-67 (100, 106, 107, 158, 
161) and by the apoptotic index (124).  The markers Ki-67 and p53 can impart 
supplementary information and are important for histopathological diagnosis with regard 
to making a clinical judgement of the consequences of “tumor-free margin”. Representation 
of telomerase activity in unfixed tumor margin tissues (64, 103, 104, 183), and not so much 
immunohistochemical proof of hTERT, (98, 107, 189, 192) can contribute to a better 
diagnostic assessment of tumor-free margins and may indicate early recurrence.   
The high proportion of BCC recurrences is a challenge to develop better selective agents for 
chemoprevention and to support them with appropriate biomarkers such as Ki-67, apoptotic 
index, telomerase or by RAR (199, 214, 225, cf. 162). 
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